Paradigm Biopharmaceuticals Ltd has released a press release.
Quarterly Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Eap - 65% pain reduction in 10 oa patients in usa
- New financial year update
- S&P DJI Announces June 2020 Quarterly Rebalance
- Block trade to institutional investors
- EAP treatment completed and Orphan Status achieved for MPS-I
Later from Paradigm Biopharmaceuticals
- Mps receives critical approvals and feedback from agencies
- Appendix 4E and 2020 Annual Report
- Paradigm Presentation to Emerging Leaders Conference
- Ema provides key path toward phase 3 trials and registration
- Extension of exclusive agreement with bene pharmachem
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals